Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $713.0 million.

  • Neurocrine Biosciences' Cash & Equivalents rose 20600.86% to $713.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $713.0 million, marking a year-over-year increase of 20600.86%. This contributed to the annual value of $713.0 million for FY2025, which is 20600.86% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Cash & Equivalents stood at $713.0 million, which was up 20600.86% from $340.2 million recorded in Q3 2025.
  • Neurocrine Biosciences' 5-year Cash & Equivalents high stood at $713.0 million for Q4 2025, and its period low was $103.8 million during Q1 2023.
  • Its 4-year average for Cash & Equivalents is $298.5 million, with a median of $293.7 million in 2023.
  • Per our database at Business Quant, Neurocrine Biosciences' Cash & Equivalents skyrocketed by 28179.19% in 2024 and then crashed by 5102.2% in 2025.
  • Neurocrine Biosciences' Cash & Equivalents (Quarter) stood at $311.1 million in 2021, then decreased by 16.71% to $259.1 million in 2023, then dropped by 10.07% to $233.0 million in 2024, then skyrocketed by 206.01% to $713.0 million in 2025.
  • Its Cash & Equivalents was $713.0 million in Q4 2025, compared to $340.2 million in Q3 2025 and $264.0 million in Q2 2025.